Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

John Mascarenhas, Joseph Scandura, Vikas Gupta, Kazuya Shimoda, James McCloskey, Firas El Chaer, Prithviraj Bose, Raajit Rampal, Andrew Srisuwananukorn, Timothy Devos, Ruben Mesa, Professor Francesco Passamonti, Srinivas Tantravahi, David Ross, Lindsay Rein, Jean-Jacques Kiladjian, Takanori Teshima, Takuji Yamauchi, Noboru Asada, Anna Halpern, Tamanna Haque, Etienne Paubelle, Noriko Fukuhara, Pankit Vachhani, Michiko Ichii, Ronald Hoffman, Marcello Rotta, Michael Keng, Stefan Wickenhauser, Karen Ansaldo, Masataka Seki, Jinny Lee, Vincent Loksa, Zhonggai Li, Jason Foulks, Sujan Kabir, Jatin Shah, Claire Harrison

Open source

DOI: 10.1182/blood-2025-482
Published: 2025-11-03
Container: Blood
Publisher: American Society of Hematology
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood-2025-482,
  title = {Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis},
  author = {John Mascarenhas and Joseph Scandura and Vikas Gupta and Kazuya Shimoda and James McCloskey and Firas El Chaer and Prithviraj Bose and Raajit Rampal and Andrew Srisuwananukorn and Timothy Devos and Ruben Mesa and Professor Francesco Passamonti and Srinivas Tantravahi and David Ross and Lindsay Rein and Jean-Jacques Kiladjian and Takanori Teshima and Takuji Yamauchi and Noboru Asada and Anna Halpern and Tamanna Haque and Etienne Paubelle and Noriko Fukuhara and Pankit Vachhani and Michiko Ichii and Ronald Hoffman and Marcello Rotta and Michael Keng and Stefan Wickenhauser and Karen Ansaldo and Masataka Seki and Jinny Lee and Vincent Loksa and Zhonggai Li and Jason Foulks and Sujan Kabir and Jatin Shah and Claire Harrison},
  year = {2025},
  journal = {Blood},
  doi = {10.1182/blood-2025-482},
  url = {https://doi.org/10.1182/blood-2025-482}
}

RIS

TY  - JOUR
TI  - Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis
AU  - John Mascarenhas
AU  - Joseph Scandura
AU  - Vikas Gupta
AU  - Kazuya Shimoda
AU  - James McCloskey
AU  - Firas El Chaer
AU  - Prithviraj Bose
AU  - Raajit Rampal
AU  - Andrew Srisuwananukorn
AU  - Timothy Devos
AU  - Ruben Mesa
AU  - Professor Francesco Passamonti
AU  - Srinivas Tantravahi
AU  - David Ross
AU  - Lindsay Rein
AU  - Jean-Jacques Kiladjian
AU  - Takanori Teshima
AU  - Takuji Yamauchi
AU  - Noboru Asada
AU  - Anna Halpern
AU  - Tamanna Haque
AU  - Etienne Paubelle
AU  - Noriko Fukuhara
AU  - Pankit Vachhani
AU  - Michiko Ichii
AU  - Ronald Hoffman
AU  - Marcello Rotta
AU  - Michael Keng
AU  - Stefan Wickenhauser
AU  - Karen Ansaldo
AU  - Masataka Seki
AU  - Jinny Lee
AU  - Vincent Loksa
AU  - Zhonggai Li
AU  - Jason Foulks
AU  - Sujan Kabir
AU  - Jatin Shah
AU  - Claire Harrison
PY  - 2025
JO  - Blood
DO  - 10.1182/blood-2025-482
UR  - https://doi.org/10.1182/blood-2025-482
ER  -

APA

Mascarenhas, J., Scandura, J., Gupta, V., Shimoda, K., McCloskey, J., Chaer, F. E., Bose, P., Rampal, R., Srisuwananukorn, A., Devos, T., Mesa, R., Passamonti, P. F., Tantravahi, S., Ross, D., Rein, L., Kiladjian, J., Teshima, T., Yamauchi, T., Asada, N., Halpern, A., Haque, T., Paubelle, E., Fukuhara, N., Vachhani, P., Ichii, M., Hoffman, R., Rotta, M., Keng, M., Wickenhauser, S., Ansaldo, K., Seki, M., Lee, J., Loksa, V., Li, Z., Foulks, J., Kabir, S., Shah, J., & Harrison, C. (2025). Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis. Blood. https://doi.org/10.1182/blood-2025-482

Source records

crossref · retrieved 2026-11-07T13:17:33.726Z